ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "polymorphism and rheumatoid arthritis (RA)"

  • Abstract Number: 585 • 2018 ACR/ARHP Annual Meeting

    The Role of Genetic Polymorphisms on the Response to Methotrexate Variations Among Rheumatoid Arthritis Patients in Saudi Arabia

    Suzan Attar1, Magdah Hagrass2, Adel Abuzenadah3, Omar Fath Aldin1, Rahaf Attar4, Rajaa Al-Raddadi5, Mansour Sulaiman2 and Ahmed Aseri2, 1Internal Medicine, Department of Internal Medicine, King Abdulaziz University, Jeddah, Saudi Arabia, 2Pharmacology, Department of Pharmacology, King Abdulaziz University, Jeddah, Saudi Arabia, 3medical technology, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia, 4internal medicine, Department of Internal Medicine, King Abdulaziz University, Jeddah, Saudi Arabia, 5Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia

    Background/Purpose: Low dose methotrexate (MTX) is one of the most commonly used disease-modifying anti-rheumatic drug for rheumatoid arthritis (RA) with excellent efficacy and safety profile. However, it…
  • Abstract Number: 1071 • 2018 ACR/ARHP Annual Meeting

    Protective Role of the Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Rs2495477 Polymorphism in Patients with Rheumatoid Arthritis

    Sara Remuzgo-Martínez1, Fernanda Genre1, Verónica Pulito-Cueto1, Alfonso Corrales1, Javier Llorca2, Verónica Mijares1, Leticia Lera-Gómez1, Virginia Portilla1, Iván Ferraz-Amaro3, Santos Castañeda4, Oreste Gualillo5, Javier Martín6, Ricardo Blanco1, Raquel Lopez-Mejías1 and Miguel Angel González-Gay7, 1Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain, Santander, Spain, 2Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), IDIVAL, Santander, Spain, Santander, Spain, 3Division of Rheumatology, Hospital Universitario de Canarias, Tenerife, Spain, Tenerife, Spain, 4Rheumatology Department, Hospital Universitario La Princesa, IIS-Princesa, Madrid, Spain, Madrid, Spain, 5SERGAS (Servizo Galego de Saude) and IDIS (Instituto de Investigación Sanitaria de Santiago), The NEIRID Group (Neuroendocrine Interactions in Rheumatology and Inflammatory Diseases), Santiago University Clinical Hospital, Santiago de Compostela, Spain, Santiago de Compostela, Spain, 6Instituto de Parasitología y Biomedicina "López-Neyra", CSIC, PTS Granada, Granada, Spain, Granada, Spain, 7Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL and School of Medicine, University of Cantabria, Santander, Spain, Santander, Spain

    Background/Purpose: RA is associated with the development of cardiovascular (CV) disease and subclinical atherosclerosis, which leads to an increased risk of CV mortality in RA…
  • Abstract Number: 2370 • 2017 ACR/ARHP Annual Meeting

    Endothelial Nitric Oxide Synthase Gene Polymorphism As a Risk Factor of Hypertension in Patients with Rheumatoid Arthritis

    Mykola Stanislavchuk1,2, Kateryna Zaichko2 and Ayad Sulaiman2, 1Internal Medicine, VNMU n.a. M. Pirogov, Vinnytsia, Ukraine, 2Rheumatology, Vinnytsia Regional Clinical Hospital, Vinnytsia, Ukraine

    Background/Purpose: Rheumatoid arthritis (RA) and hypertension (HT) are multifactorial polygenic diseases. The incidence of hypertension in patients with RA is higher than in the general…
  • Abstract Number: 13 • 2016 ACR/ARHP Annual Meeting

    Genetic Variants of the Vasoactive Intestinal Peptide (VIP) Gen in Association with Rheumatoid Arthritis Treatment Requirements

    Iria V. Seoane1, Carmen Martinez2, Yasmina Juarranz1, Rosario García-Vicuña3, Eva Tomero4, Rosa P Gomariz1, Isidoro Gonzalez-Alvaro3 and Amalia Lamana5, 1Cellular Biology, School of Biology. Universidad Complutense de Madrid, Madrid, Spain, 2Cellular Biology, School of Medicine. Universidad Complutense de Madrid, Madrid, Spain, 3Rheumatology, Rheumatology Service, Hospital Universitario de La Princesa, IIS-IP, Madrid, Spain, 4Rheumatology, Hospital Universitario de la Princesa, Madrid, Spain, 5Rheumatology, Hospital Universitario de La Princesa. IIS Princesa, Madrid, Spain

    Background/Purpose: Biomarkers to recognize patients with a more intensive therapy necessity in rheumatoid arthritis are essential and scarce. VIP has shown immunoregulatory properties both in…
  • Abstract Number: 69 • 2016 ACR/ARHP Annual Meeting

    IL-32 Promoter SNP rs4786370 Predisposed to Modified Lipoprotein Profiles in Patients with Rheumatoid Arthritis

    Michelle S.M.A. Damen1, Rabia Agca2, Suzanne Holewijn3, Jacqueline de Graaf1, Jéssica C. Dos Santos1,4, Piet L van Riel5, J Fransen6, Marieke J.H. Coenen7, Mike T. Nurmohamed8, M.G. Netea1, Charles Dinarello9, L.A.B. Joosten1, Bas Heinhuis1 and Calin Popa10, 1Internal Medicine, Radboud University Medical Center, Nijmegen, Netherlands, 2Rheumatology, Amsterdam Rheumatology and immunology Center, Location Reade, Amsterdam, Netherlands, 3Rijnstate Ziekenhuis, Arnhem, Netherlands, 4Instituto de Patologia Tropical e Saúde Pública, Goiás, Brazil, 5Scientific Institute for Quality of Healthcare, Radboud University Medical Center, Nijmegen, Netherlands, 6Department of Rheumatolgy, Radboud UMC, Nijmegen, Netherlands, 7Human Genetics (855), Department of Human Genetics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 8Rheumatology, Amsterdam Rheumatology and immunology Center, Location VU University Medical Center, Amsterdam, Netherlands, Amsterdam, Netherlands, 9Department of Medicine, Division of Infectious Diseases, University of Colorado, Denver, CO, 10Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands

    Background/Purpose:  Patients with a chronic inflammatory disease such as rheumatoid arthritis (RA) are at higher risk of developing cardiovascular diseases (CVD). Interleukin (IL)-32 has previously…
  • Abstract Number: 1572 • 2016 ACR/ARHP Annual Meeting

    Relationship Between KDR (VEGFR2) Gene Polymorphisms and Serum KDR Protein Levels in Patients with Rheumatoid Arthritis

    Agnieszka Paradowska-Gorycka1, Barbara Stypinska2, Andrzej Pawlik3, Damian Malinowski3, Katarzyna Romanowska-Próchnicka4, Ewa Haladyj5, Malgorzata Manczak6 and Marzena Olesinska7, 1Department of Biochemistry and Molecular Biology, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland, 2Department of Biochemistry and Molecular Biology, National Institute of geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland, 3Department of Pharmacology, Pomeranian Medical University, Szczecin, Poland, 4Department of Pathophysiology, Medical University of Warsaw and Department of Connective Tissue Diseases, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland, 5Department of Connective Tissue Diseases, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland, 6Department of Epidemiology and Health Promotion, National Institute of geriatrics, Rheumatology and Rehabilitation,, Warsaw, Poland, 7Department of Connective Tissue Disease, National Institute of Geriatrics, Rheumatology and Rehabilitation,, Warsaw, Poland

    Background/Purpose:  Rheumatoid arthritis (RA) is one of the chronic autoimmune diseases, with genetic and environmental predisposition, and synovial angiogenesis is considered to be a notable…
  • Abstract Number: 105 • 2015 ACR/ARHP Annual Meeting

    Analysis of the Association of PTGER4 Gene Variants with Radiological Joint Damage in Rheumatoid Arthritis

    Luis Rodriguez-Rodriguez1,2, J. Ivorra-Cortes3, Francisco David Carmona4, Javier Martín5, Alejandro Balsa6, H.W. van Steenbergen7, A. H. M. van der Helm- van Mil8, Isidoro González-Alvaro9 and Benjamín Fernández-Gutiérrez10, 1Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain, 2Hospital Clínico San Carlos, Department of Rheumatology, Madrid, Spain, 3Rheumatology, University Hospital la Fe, Valencia, Spain, 4Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, PTS-Granada, Granada, Spain, 5Instituto de Parasitología y Biomedicina López- Neyra, IPBLN-CSIC, PTS-Granada, Granada, Spain, 6Rheumatology, La Paz University Hospital-Rheumatology Department, Madrid, Spain, 7Leiden University Medical Center, Leiden, Netherlands, 8Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 9Rheumatology Department, Hospital Universitario la Princesa, IIS-Princesa, Madrid, Spain, 10Department of Rheumatology, Hospital Clínico San Carlos, Madrid, Spain

    Background/Purpose: PTGER4(prostaglandin E receptor 4) is implicated in immune regulation and bone metabolism. The aim of this study was to analyze the role of single…
  • Abstract Number: 1608 • 2015 ACR/ARHP Annual Meeting

    Protective Role of the Vitamin D Receptor Apai (rs7975232) Polymorphism Against Subclinical Atherosclerosis in Patients with Rheumatoid Arthritis from Northern Spain

    Raquel López-Mejías1, Fernanda Genre1, Sara Remuzgo-Martínez1, Gema Robledo2, Begoña Ubilla1, Veronica Mijares1, Javier Llorca3, Montserrat Robustillo-Villarino4, Alfonso Corrales1, Carlos González-Juanatey5, Jose A. Miranda-Filloy6, Trinitario Pina7, Ricardo Blanco7, Esther Vicente8, Juan José Alegre9, Cesar Magro10, Enrique Raya11, Beatriz Tejera12, Marco A Ramírez Huaranga13, Ivan Ferraz-Amaro12, Santos Castañeda14, Javier Martín2 and Miguel A. Gonzalez-Gay1,15, 1Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, IDIVAL, Santander, Spain, 2Institute of Parasitology and Biomedicine López-Neyra, IPBLN-CSIC, Granada, Spain, 3Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), IDIVAL, Santander, Spain, 4Rheumatology Department, Hospital Universitario Doctor Peset, Valencia, Spain, 5Cardiology Division, Hospital Lucus Augusti, Lugo, Spain, 6Rheumatology Division, Hospital Lucus Augusti, Lugo, Spain, 7Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, 8Rheumatology Department, Hospital Universitario la Princesa, IIS-Princesa, Madrid, Spain, 9Rheumatology, Rheumatology Department, Hospital Universitario Doctor Peset, Valencia, Spain, 10Rheumatology Department, Hospital Clínico San Cecilio, Granada, Spain, 11Rheumatology, Hospital Clínico San Cecilio, Granada, Spain, 12Rheumatology Division, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, 13Rheumatology Department, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain, 14Rheumatology, H.U. La Princesa, Madrid, Spain, 15Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

    Background/Purpose: Several vitamin D receptor (VDR) polymorphisms have been associated with cardiovascular (CV) and autoimmune diseases. Carotid plaques are surrogate markers of severe atherosclerotic disease.…
  • Abstract Number: 1609 • 2015 ACR/ARHP Annual Meeting

    Lack of Association Between ZHX2, Lepr, Gckr and ASCL1 and Carotid Intima-Media Thickness, Carotid Plaques and Cardiovascular Disease in Patients with Rheumatoid Arthritis

    Raquel López-Mejías1, Fernanda Genre1, Sara Remuzgo-Martínez1, Montserrat Robustillo-Villarino2, Alfonso Corrales1, Javier Llorca3, Carlos González-Juanatey4, Begoña Ubilla1, Jose A. Miranda-Filloy5, Veronica Mijares1, Trinitario Pina6, Ricardo Blanco6, Juan José Alegre2, Marco A Ramírez Huaranga7, Maria D Mínguez Sánchez7, Carmen Gomez Vaquero8, Luis Rodriguez Rodriguez9, Benjamin Fernandez Gutierrez9, Alejandro Balsa10, Dora Pascual-Salcedo10, Francisco Lopez Longo11, Patricia E. Carreira12, Cesar Magro13, Enrique Raya14, Beatriz Tejera15, Ivan Ferraz-Amaro15, Esther Vicente16, Isidoro González-Alvaro16, Santos Castañeda17, Javier Martín18 and Miguel A. Gonzalez-Gay1,19, 1Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, IDIVAL, Santander, Spain, 2Rheumatology Department, Hospital Universitario Doctor Peset, Valencia, Spain, 3Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), IDIVAL, Santander, Spain, 4Cardiology Division, Hospital Lucus Augusti, Lugo, Spain, 5Rheumatology Division, Hospital Lucus Augusti, Lugo, Spain, 6Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, 7Rheumatology Department, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain, 8Department of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, 9Department of Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, 10Department of Rheumatology, Hospital La Paz, Madrid, Spain, 11Department of Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, 12Department of Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, 13Rheumatology Department, Hospital Clínico San Cecilio, Granada, Spain, 14Rheumatology, Hospital Clínico San Cecilio, Granada, Spain, 15Rheumatology Division, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, 16Rheumatology Department, Hospital Universitario la Princesa, IIS-Princesa, Madrid, Spain, 17Rheumatology, H.U. La Princesa, Madrid, Spain, 18Institute of Parasitology and Biomedicine López-Neyra, IPBLN-CSIC, Granada, Spain, 19Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

    Background/Purpose: Rheumatoid arthritis (RA) is a polygenic disease associated with accelerated atherosclerosis and increased cardiovascular (CV) mortality. Recent studies have identified the ZHX2 rs11781551 polymorphism…
  • Abstract Number: 2452 • 2014 ACR/ARHP Annual Meeting

    Protective Effect of the IL33 rs3939286 Gene Polymorphism in the Development of Subclinical Atherosclerosis in Patients with Rheumatoid Arthritis

    Raquel López-Mejías1, Fernanda Genre1, Mercedes García-Bermúdez2, Alfonso Corrales1, Carlos González-Juanatey3, Begoña Ubilla1, J. Llorca4, Encarnación Amigo5, Jose A. Miranda-Filloy6, Trinitario Pina Murcia1, Ricardo Blanco7, Santos Castañeda8, Javier Martin9 and Miguel A González-Gay1, 1Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, IDIVAL, Santander, Spain, 2Immunology and Cellular Biology, Instituto de Parasitologia y Biomedicina López-Neyra, IPBLN-CSIC, Granada, Spain, 3Hospital Universitario Lucus Augusti. Cardiology Division, Lugo, Spain, 4Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), IDIVAL, Santander, Spain, 5Hospital Universitario Lucus Augusti, Rheumatology Division, Lugo, Spain, 6Rheumatology, Division of Rheumatology, Hospital Lucus Augusti, Lugo, Spain, 7Hospital Marques de Valdecilla, Santander, Spain, 8Rheumatology, Hospital Universitario de La Princesa, IISP, Madrid, Spain, 9Immunology, Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Armilla (Granada), Spain

    Background/Purpose: Rheumatoid arthritis (RA) is a complex inflammatory disease characterized by chronic inflammation, accelerated atherosclerosis and increased cardiovascular (CV) mortality. Interleukin 33 (IL-33) is a…
  • Abstract Number: 1123 • 2014 ACR/ARHP Annual Meeting

    Impact of Genes Modulating Serum Low-Density Lipoprotein Cholesterol Levels on Progression of Joint Destruction in Japanese Patients with Rheumatoid Arthritis

    Shinji Yoshida1, Katsunori Ikari1, Koichiro Yano1, Yoshiaki Toyama2, Atsuo Taniguchi3, Hisashi Yamanaka1 and Shigeki Momohara3, 1Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, 2Department of Orthopaedic Surgery, Keio University School of Medicine, Tokyo, Japan, 3Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan

    Background/Purpose Patients with rheumatoid arthritis (RA) have a higher prevalence of dyslipidemia than healthy individuals. Since RA is a chronic inflammatory disease, an inflammatory response…
  • Abstract Number: 2459 • 2014 ACR/ARHP Annual Meeting

    Osteoprotegerin CGA Haplotype Protection Against Cerebrovascular Complications in Anti-CCP Negative Patients with Rheumatoid Arthritis

    Fernanda Genre1, Raquel López-Mejías1, Mercedes García-Bermúdez2, Santos Castañeda3, Carlos González-Juanatey4, Javier Llorca5, Alfonso Corrales1, Begoña Ubilla1, Jose A. Miranda-Filloy6, Encarnación Amigo6, Trinitario Pina Murcia1, Carmen Gómez-Vaquero7, Luis Rodriguez-Rodriguez8, Benjamin Fernández Gutierrez8, Alejandro Balsa9, Dora Pascual-Salcedo9, Francisco Javier López-Longo10, Patricia Carreira11, Ricardo Blanco12, Isidoro González-Alvaro13, Javier Martin14 and Miguel A González-Gay1, 1Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, IDIVAL, Santander, Spain, 2Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Granada, Spain, 3Rheumatology, Hospital Universitario de La Princesa, IISP, Madrid, Spain, 4Hospital Universitario Lucus Augusti. Cardiology Division, Lugo, Spain, 5Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), IDIVAL, Santander, Spain, 6Hospital Universitario Lucus Augusti, Rheumatology Division, Lugo, Spain, 7Rheumatology Service, Hospital Universitari de Bellvitge - IDIBELL, Barcelona, Spain, 8Hospital Clínico San Carlos, Department of Rheumatology, Madrid, Spain, 9Hospital Universitario La Paz, Department of Rheumatology, Madrid, Spain, 10Hospital General Universitario Gregorio Marañón, Department of Rheumatology, Madrid, Spain, 11Hospital Universitario 12 de Octubre, Department of Rheumatology, Madrid, Spain, 12Hospital Marques de Valdecilla, Santander, Spain, 13Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, 14Immunology, Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Armilla (Granada), Spain

    Background/Purpose: Rheumatoid arthritis is an inflammatory disease with a high incidence of cardiovascular disease due to accelerated atherosclerosis. Osteoprotegerin (OPG) has been associated with an…
  • Abstract Number: 157 • 2013 ACR/ARHP Annual Meeting

    Application Of a Multiplex Gene Polymorphism Assay For Variants Associated With Rheumatoid Arthritis Susceptibility: Results Of 168 Single Nucleotide Polymorphisms In The Optima Study

    Jeffrey F. Waring1, Viswanath Devanarayan2, Kenneth Idler1, Feng Hong2, Josef S. Smolen3, Arthur Kavanaugh4, Hartmut Kupper5, Hendrik Schulze-Koops6 and Alla Skapenko7, 1AbbVie Inc., North Chicago, IL, 2AbbVie Bioresearch Center, Worchester, MA, 3Medical University of Vienna and Hietzing Hospital, Vienna, Austria, 4University of California San Diego, La Jolla, CA, 5AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, 6Division of Rheumatology, University of Munich, Munich, Germany, 7Division of Rheumatology and Clinical Immunology, University of Munich, Munich, Germany

    Background/Purpose: Genetic factors have been identified that may be associated with the development and severity of rheumatoid arthritis (RA), disease progression, or response to treatment.…
  • Abstract Number: 2483 • 2012 ACR/ARHP Annual Meeting

    Folic Acid Pathway Single Neucelotide Polymorphisms Associated with Methotrexate-Related Significant Adverse Events

    Lisa A. Davis1, Brooke Ivan Polk2, Alyse D. Mann3, Roger K. Wolff4, Gail S. Kerr5, Andreas M. Reimold6, Grant W. Cannon7, Ted R. Mikuls8 and Liron Caplan9, 1Div of Rheumatology, Univ of Colorado School of Med, Aurora, CO, 2University of Colorado Medical School, Aurora, CO, 3Research, Denver VA Medical Center, Denver, CO, 4University of Utah, Salt Lake City, UT, 5Rheumatology, Washington DC VAMC, Georgetown and Howard University, Washington, DC, 6Rheumatology, Dallas VA and University of Texas Southwestern, Dallas, TX, 7Division of Rheumatology, George E. Wahlen VA Medical Center, Salt Lake City, UT, 8Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, 9Div of Rheumatology, Denver VA and University of Colorado School of Medicine, Aurora, CO

      Background/Purpose: Methotrexate (MTX) is the cornerstone medication in the treatment of rheumatoid arthritis (RA). While MTX has been associated with a number of adverse…
  • Abstract Number: 1179 • 2012 ACR/ARHP Annual Meeting

    Vitamin D Receptor Polymorphisms Are Associated with Clinical Outcomes and IgM Responses to Common Pathogens but Not Baseline Disease Activity in Early Inflammatory Arthritis

    Carol A. Hitchon1, Linda Larcombe1, Neeloffer Mookherjee2, Christine A. Peschken3, Marianna M. Newkirk4 and Hani S. El-Gabalawy5, 1University of Manitoba, Winnipeg, MB, Canada, 2Centre for Proteomics, University of Manitoba, Winnipeg, MB, Canada, 3RR 149G, University of Manitoba, Winnipeg, MB, Canada, 4Medicine, McGill University Health Centre, Montreal, QC, Canada, 5Arthritis Centre, University of Manitoba, Winnipeg, MB, Canada

    Background/Purpose: Vitamin D (VitD) exerts immunoregulatory activities of potential importance to rheumatoid arthritis and acts by binding to nuclear vitamin D receptors (VDRs) and regulating…
  • 1
  • 2
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology